查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604744

金諾芬市場：依形式、適應症分類 - 2025-2030 年全球預測

Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年金諾芬市值為2.092億美元，預計到2024年將達到2.1899億美元，複合年成長率為4.81%，到2030年將達到2.9085億美元。

金諾芬主要被認為是一種抗風濕藥，可用於治療類風濕性關節炎。除了這一主要用途之外，研究還表明其在多種自體免疫疾病和作為抗寄生蟲藥物中的潛在用途，證明了其在多個治療領域的多功能性。對金諾芬的需求是由於在典型治療無法產生預期效果或表現出嚴重副作用的情況下需要有效的治療方法，並且它在利基醫療條件下的使用強調了未來的價值。由於其低毒性和口服生物有效性利用度，金諾芬的應用範圍正在擴大，這為患者提供了更大的便利，並比注射劑具有競爭優勢。最終用途主要是在製藥領域，隨著安全性和有效性研究的進展，有可能成為動物用藥品。

主要市場統計
基準年[2023] 2.092 億美元
預計年份 [2024] 21899萬美元
預測年份 [2030] 29085萬美元
複合年成長率（%） 4.81%

市場洞察表明，對具有良好治療效果的金基化合物的需求不斷成長，其中金諾芬處於領先地位。影響成長的關鍵因素包括自體免疫疾病的增加以及對癌症和神經退化性疾病重新利用的持續探索。精準醫療的出現和金諾芬聯合治療的探索可以釋放巨大的市場潛力，並為擴張和利潤提供堅實的途徑。然而，與金基藥物相關的嚴格監管路徑、潛在副作用和高成本等限制因素普遍存在，這可能會阻礙廣泛採用和市場進入。

為了利用新的商機，需要進行技術創新，重點是提高金諾芬的生物有效性，減少副作用，並將其應用於罕見和難以治療的疾病。市場競爭是創新主導的，注重研發以維持和擴大市場佔有率。與研究機構的策略聯盟和臨床試驗投資可以有效應對現有挑戰並擴大成長前景。識別與治療領域（尤其是慢性病）相關的未滿足需求，是利用未滿足關鍵字的廣泛效用的絕佳機會，最終推動業務成長和市場滲透。

市場動態：揭示快速發展的金諾芬市場的關鍵市場洞察

金諾芬市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 類風濕性關節炎盛行率上升，需要替代治療
    • 寄生蟲感染、某些癌症、金諾芬作為抗病毒藥物的潛力
    • 政府和非政府資助慢性病和癌症研究
  • 市場限制因素
    • 與金諾芬相關的副作用
  • 市場機會
    • 探索金諾芬在新治療應用的有效性
    • 製藥公司與研究機構的合作
  • 市場挑戰
    • 複雜的監管環境和高昂的臨床試驗成本

波特的五力：駕馭金諾芬市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解金諾芬市場的外部影響

外部宏觀環境因素在塑造金諾芬市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解金諾芬市場的競爭狀況

對金諾芬市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣金諾芬市場供應商的績效評估

FPNV 定位矩陣是評估 Auranofin 市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製金諾芬市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，金諾芬市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 類風濕性關節炎盛行率上升以及對替代治療的需求
      • 金諾芬具有對抗寄生蟲感染疾病、某些癌症和抗病毒藥物的潛在作用。
      • 政府和非政府資助慢性病和癌症研究
    • 抑制因素
      • 與金諾芬相關的副作用
    • 機會
      • 探索金諾芬在新治療應用的有效性
      • 製藥公司與研究機構的合作
    • 任務
      • 複雜的監管環境和高成本
  • 市場區隔分析
    • 形式：金諾芬膠囊的相容性，可將活性藥物輸送到全身並確保均勻分佈
    • 適應症：由於發炎涉及細胞機制，金諾芬被推薦用於治療血清陽性 RA。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 金諾芬市場：依形式

  • 膠囊
  • 錠劑

第7章 金諾芬市場依適應症分類

  • 血清類風濕性關節炎類風濕性關節炎
  • 血清類風濕性關節炎類風濕性關節炎

第8章 金諾芬美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太地區金諾芬市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲金諾芬市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 關節炎基金會投資 110 萬美元用於頑固性類風濕性關節炎研究
  • 戰略分析和建議

公司名單

  • Chugai Pharmaceutical Co Ltd
  • LGM Pharma
  • Prometheus Laboratories Inc.
  • Sebela Pharmaceuticals Inc.
  • Taj Pharmaceuticals Limited
  • Xediton Pharmaceuticals
Product Code: MRR-F97DD5A7D98B

The Auranofin Market was valued at USD 209.20 million in 2023, expected to reach USD 218.99 million in 2024, and is projected to grow at a CAGR of 4.81%, to USD 290.85 million by 2030.

Auranofin is primarily recognized as an anti-rheumatic agent for its utility in the treatment of rheumatoid arthritis. Its scope extends beyond this primary application, as research suggests potential usage in addressing various autoimmune diseases and as an anti-parasitic agent, demonstrating its versatility in multiple therapeutic areas. The necessity for Auranofin is driven by the need for effective therapies in conditions where typical treatments either haven't delivered desired outcomes or present severe side effects, emphasizing its prospective value in niche medical conditions. The application scope of Auranofin is expanding, propelled by its low toxicity profile and oral bioavailability, which makes it convenient for patients and offers a competitive edge over injectable counterparts. End-use primarily involves the pharmaceutical sector and possibly veterinary medicine as research into safety and efficacy continues.

KEY MARKET STATISTICS
Base Year [2023] USD 209.20 million
Estimated Year [2024] USD 218.99 million
Forecast Year [2030] USD 290.85 million
CAGR (%) 4.81%

Market insights reveal a growing demand for gold-based compounds due to their promising therapeutic profiles, with Auranofin leading as a frontrunner. Key factors influencing its growth include increased autoimmune disease prevalence and ongoing research into repurposing for cancer and neurodegenerative diseases. The advent of precision medicine and the exploration of Auranofin in combination therapies could unlock significant market potentials, providing robust avenues for expansion and profit. However, predominant limitations include stringent regulatory paths, potential adverse effects, and the high costs associated with gold-based drugs, which may impede widespread adoption and market accessibility.

To capitalize on emerging opportunities, innovation should focus on enhancing Auranofin's bioavailability, reducing side effects, and exploring its use in rare and difficult-to-treat diseases. The market's nature is competitive and innovation-driven, with a strong emphasis on research and development to maintain and grow market share. Strategic collaborations with research institutions and investments in clinical trials could effectively address existing challenges and amplify growth prospects. Identifying unmet needs in therapeutic areas, particularly those associated with chronic diseases, represents an excellent opportunity for leveraging Auranofin's broad spectrum utility, ultimately driving business growth and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Auranofin Market

The Auranofin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of rheumatoid arthritis and the need for alternative treatments
    • Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
    • Governmental and non-governmental funding for chronic diseases and cancer research
  • Market Restraints
    • Side effects associated with Auranofin
  • Market Opportunities
    • Exploring auranofin's efficacy in new therapeutic applications
    • Partnerships between pharmaceutical companies and research institutions
  • Market Challenges
    • Complex regulatory landscape and the high cost of clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Auranofin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Auranofin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Auranofin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Auranofin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Auranofin Market

A detailed market share analysis in the Auranofin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Auranofin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Auranofin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Auranofin Market

A strategic analysis of the Auranofin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Capsule and Tablet.
  • Based on Indication, market is studied across Seronegative Rheumatoid Arthritis and Seropositive Rheumatoid Arthritis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
      • 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
      • 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with Auranofin
    • 5.1.3. Opportunities
      • 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
      • 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
    • 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Auranofin Market, by Form

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Auranofin Market, by Indication

  • 7.1. Introduction
  • 7.2. Seronegative Rheumatoid Arthritis
  • 7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Auranofin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Chugai Pharmaceutical Co Ltd
  • 2. LGM Pharma
  • 3. Prometheus Laboratories Inc.
  • 4. Sebela Pharmaceuticals Inc.
  • 5. Taj Pharmaceuticals Limited
  • 6. Xediton Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
  • FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AURANOFIN MARKET DYNAMICS
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023